Kymera Therapeutics

Kymera Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update

Initiated Phase 1 first-in-human dosing of KT-474, a first-in-class oral IRAK4 degrader to treat immune-inflammatory diseases Declared KT-333 as STAT3 development candidate for liquid and solid tumor indications and commenced IND-enabling activities Strong financial position to support continued